WE APPRECIATE Dr Calabrese's commentary on our study of ω3 fatty acids as a new treatment of bipolar disorder. He correctly points out both the exciting aspects of ω3 fatty acids as a therapy for patients with bipolar disorder, as well as the methodological shortcomings of our preliminary trial.
Dr Calabrese's constructive criticisms of the study methodology are reasonable and are issues that future studies should address. When evaluating the methods for our current study, it is important to keep in mind that this was a preliminary study designed to demonstrate the prophylactic efficacy of ω3 fatty acids as mood stabilizers. It was intended to be a longer-term trial, but 2 factors led to premature termination of the study. First, the preplanned 4-month interim data analysis revealed an unacceptably high relapse rate among the patients receiving placebo, which led us to conclude that it would be more ethical to stop the pilot study, and evaluate the available data. In addition, a shortage of study drug from the National Institutes of Health would have forced a later, but still premature, termination of the study.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Psychiatry editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.